Our areas
of focus

Bladder cancer

Bladder cancer is the fourth most common cancer in men in the US. At Pfizer, we are committed to improving care for people with bladder cancer. We offer a treatment for advanced bladder cancer. We are also exploring the use of combination therapy in earlier stages of the disease while also testing additional medicines to expand future treatment options.

Explore bladder cancer

Prostate cancer

Prostate cancer affects millions of men, with cases rising as the population ages. When prostate cancer spreads (in about 1 out of 5 cases), survival rates decline. Advances in treatments are creating new possibilities for patients with prostate cancer. Pfizer is providing research and development in this field.

Explore prostate cancer

Kidney cancer

Kidney cancer impacts thousands of people in the US every year, with half of the cases linked to lifestyle factors. New treatments, like targeted therapies and immunotherapies, are changing care for some patients. Pfizer has been changing the way advanced kidney cancer is treated. Currently, we have 3 approved treatments for kidney cancer.

Lung cancer

Lung cancer remains the leading cause of cancer-related deaths among men and women, and it’s the second most common cancer in the US. Pfizer offers multiple approved medicines that treat several forms of non-small cell lung cancer (NSCLC.) We are also studying additional potential treatments for certain types of NSCLC.

Explore lung cancer

Head & neck

About 4% of all cancers in the US are head and neck cancers. Despite an improved understanding of the molecular basis of these tumors, the identification of biomarkers, and the introduction of new treatments, outcomes have mostly remained unchanged for decades. Pfizer is conducting clinical trials to explore the potential of antibody-drug conjugate (ADC) medicines for squamous cell carcinoma of the head and neck, including the potential for combination therapy.

Additional tumor types

In addition to breast, bladder, prostate, kidney, blood, lung, and head and neck cancers, other tumor types such as cervical, colorectal, and skin cancers are some of the most common cancers in the US. Pfizer offers treatments and continues to study ways to treat these cancers, offering potential hope for patients who need a new treatment option.

For approximately 15% of patients with cervical cancer, their cancer has already spread at the time of diagnosis. Among women who are diagnosed with recurrent cervical cancer, the 5-year survival is under 5%. Recurrent or metastatic cervical cancer is a devastating and mostly incurable disease, with an urgent need for more treatment options. Pfizer offers a medicine for cervical cancer, providing hope for patients who need additional treatment options.

Colorectal cancer (CRC), in patients whose cancer has spread, can have a poor prognosis, with a 5-year survival rate of under 20%. Breakthroughs in precision medicine and treatments are transforming care for patients with colorectal cancer, offering them more options.

Explore colorectal cancer

Melanoma skin cancer is the fifth most common cancer in the US and causes the majority of skin cancer deaths. Pfizer offers a medicine that fills a need for people with advanced melanoma who are positive for a specific gene mutation.